CClinicalTrials.gg
Status unknownNCT04117828Updated Nov 8, 2019

Assessment of Glycemic Index of Different Dates

An interventional study of Dates in Glycemic Index and Glycemic Load, sponsored by Aga Khan University. Status unknown at 1 site in Pakistan. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-11-08.

Sponsored by Aga Khan University · Not applicable, Interventional, and Other

The sponsor has not verified this record recently (last verified Nov 2019), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

Glycemic Index is a system of classification of different foods with significant levels of carbohydrates based on how they affect blood glucose levels after being consumed. In this study we will compare glycemic index of different varieties

Read the detailed description

Glycemic Index is a system of classification of different foods with significant levels of carbohydrates based on how they affect blood glucose levels after being consumed. Despite being a significant parameter of blood glucose, GI does not depict the effect of the food when taken in a controlled recommended amount, and so the Glycemic Loads (GL) must also be calculated, thereby measuring the impact on glycemic levels after consumption of standard food portion sizes. Dates are high energy foods consumed in various parts of the world, are known to be a source of several important nutrients and are also shown to have significant impacts in preventing illnesses due to their anti-inflammatory and anti-microbial actions as well as preventative action against oxidative reactions The greatly frequent consumption of dates necessitates the identification of their GI and GL to ensure whether consumption is beneficial and safe for individuals. The objective of the study is to determine and compare the values of GI and GL of three varieties of dates in order to assess their safe consumption by individuals

02

Conditions studied

  • Glycemic Index and Glycemic Load
03

In context

Lead sponsor

Aga Khan University is the lead sponsor of 290 studies on the registry; 44 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • General population from AKU
  • Adult ages (18- 60 years) will be included in the study

Exclusion criteria

Exclusion Criteria:

  • Individuals with Dates/Ajwa allergy
  • Pregnant women and individuals with diabetes, metabolic syndrome or any other co-morbidity will be excluded
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Active comparator
    Control

    50 g of glucose will be given to the individuals

    Dietary Supplement: Dates

  • Experimental
    1st Intervention group

    50 g of Aseel dates will be given to the individuals

    Dietary Supplement: Dates

  • Experimental
    2nd Intervention group

    50 g of Ajwa dates will be given to the individuals

    Dietary Supplement: Dates

  • Experimental
    3rd Intervention group

    50 g of Karbala dates will be given to the individuals

    Dietary Supplement: Dates

Interventions

  • Dietary supplementDates

    Phoenix dactylifera, commonly known as date or date palm is a flowering plant species in the palm family, Arecaceae. Dates are the fruit of the date palm tree, which is grown in many tropical regions of the world. Dates provide a wide range of essential nutrients, and has certain protective effects on health of individuals.

06

What researchers measure

Primary outcomes

  1. Blood Glucose level

    Estimation of glycemic index and glycemic load

    Time frame: 1 week

07

Study locations

1 of 1 sites recruiting
  • Agha Khan University Hospital
    Karachi, Sindh 74800, Pakistan
    Recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 8, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04117828
Lead sponsor
Aga Khan University
Responsible party
NASEER AHMED (Assistant Professor, Aga Khan University) — Principal investigator
First posted
Oct 7, 2019
Start date
Oct 14, 2019
Primary completion
Oct 20, 2019
Completion
Nov 2019 (estimated)
Last update
Nov 8, 2019

Study contacts

Naseer Ahmed, Ph.D
Contact
dr.naseer99@gmail.com
3333382013
Javeria Farooq, M.Phil
Contact
javeria.farooq@aku.edu
Naseer Ahmed, Ph.D
principal investigator · AKU

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion